tiprankstipranks
Advertisement
Advertisement

JP:4547 Stock Latest News

Kissei Pharmaceutical Sets Share Buyback Framework but Executes No Purchases in May
Company AnnouncementsKissei Pharmaceutical Sets Share Buyback Framework but Executes No Purchases in May
3h ago
Kissei Files Japan NDA for IDH1-Targeting AML Drug Olutasidenib
PremiumCompany Announcements
Kissei Files Japan NDA for IDH1-Targeting AML Drug Olutasidenib
7d ago
Kissei Tightens Safety Warnings on TAVNEOS After Serious Liver Risk Cases
PremiumCompany Announcements
Kissei Tightens Safety Warnings on TAVNEOS After Serious Liver Risk Cases
13d ago
Kissei Restricts TAVNEOS Use in Japan After Global Safety and Data Concerns
PremiumCompany Announcements
Kissei Restricts TAVNEOS Use in Japan After Global Safety and Data Concerns
19d ago
Kissei Pharmaceutical Posts Record Sales as R&D Investment and Overseas Growth Intensify
PremiumCompany Announcements
Kissei Pharmaceutical Posts Record Sales as R&D Investment and Overseas Growth Intensify
22d ago
Kissei Pharmaceutical Launches ¥6 Billion Share Buyback and Cancellation Plan
PremiumCompany AnnouncementsKissei Pharmaceutical Launches ¥6 Billion Share Buyback and Cancellation Plan
23d ago
Kissei Pharmaceutical Details FY2026 Results and R&D Pipeline in Supplementary Report
Premium
Company Announcements
Kissei Pharmaceutical Details FY2026 Results and R&D Pipeline in Supplementary Report
23d ago
Kissei Pharmaceutical Swings to Operating Loss but Lifts Payouts and Eyes Profit Recovery
Premium
Company Announcements
Kissei Pharmaceutical Swings to Operating Loss but Lifts Payouts and Eyes Profit Recovery
23d ago
KSPHF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
KSPHF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
25d ago
Kissei sublicenses AML drug olutasidenib to Orient EuroPharma in Taiwan
PremiumCompany Announcements
Kissei sublicenses AML drug olutasidenib to Orient EuroPharma in Taiwan
1M ago
Kissei Pharmaceutical Names Research Chief Keiji Miyazawa as New President and COO
PremiumCompany Announcements
Kissei Pharmaceutical Names Research Chief Keiji Miyazawa as New President and COO
1M ago
Kissei Launches Yselty in Japan, Expanding Global Uterine Fibroid Treatment Portfolio
PremiumCompany Announcements
Kissei Launches Yselty in Japan, Expanding Global Uterine Fibroid Treatment Portfolio
3M ago
Kissei Pharmaceutical to Allocate ¥2.4 Billion in Treasury Shares to Employee Shareholding Plan
PremiumCompany AnnouncementsKissei Pharmaceutical to Allocate ¥2.4 Billion in Treasury Shares to Employee Shareholding Plan
3M ago
Kissei Pharmaceutical Marks 80th Anniversary With Special Dividends and Higher Payout
Premium
Company Announcements
Kissei Pharmaceutical Marks 80th Anniversary With Special Dividends and Higher Payout
4M ago
Kissei Pharmaceutical Releases Supplementary Materials on Nine-Month FY2025 Results and R&D Pipeline
Premium
Company Announcements
Kissei Pharmaceutical Releases Supplementary Materials on Nine-Month FY2025 Results and R&D Pipeline
4M ago
Kissei Pharmaceutical Lifts Sales and Earnings, Boosts Payouts Despite Operating Loss
PremiumCompany Announcements
Kissei Pharmaceutical Lifts Sales and Earnings, Boosts Payouts Despite Operating Loss
4M ago
Kissei Pharmaceutical Co (KSPHF) Q3 Earnings Cheat Sheet
PremiumPre-Earnings
Kissei Pharmaceutical Co (KSPHF) Q3 Earnings Cheat Sheet
4M ago
Kissei Wins Japan Approval for Oral GnRH Antagonist Yselty for Uterine Fibroids
PremiumCompany Announcements
Kissei Wins Japan Approval for Oral GnRH Antagonist Yselty for Uterine Fibroids
5M ago
Kissei Pharmaceutical initiated with a Neutral at UBS
PremiumThe Fly
Kissei Pharmaceutical initiated with a Neutral at UBS
6M ago
Kissei Pharmaceutical Adjusts Dividend Payment Date
PremiumCompany AnnouncementsKissei Pharmaceutical Adjusts Dividend Payment Date
6M ago
Kissei Pharmaceutical Co Reports Growth Amid Increased R&D Investment
Premium
Company Announcements
Kissei Pharmaceutical Co Reports Growth Amid Increased R&D Investment
7M ago
Kissei Pharmaceutical Revises Financial Forecast with Positive Outlook
Premium
Company Announcements
Kissei Pharmaceutical Revises Financial Forecast with Positive Outlook
7M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >